MBBS OSCE · Dermatology / Allergy / Therapeutics
OSCE — antihistamines and itch: urticaria pathway vs non-histaminergic pruritus
An 8-minute OSCE station on using newer-generation H1 antihistamines at standard and four-fold updosed regimens for chronic spontaneous urticaria, recognising when itch will not respond to antihistamines, and using first-generation sedating agents only as a last resort.
8 min stationSource-verified ·
On this page
Study tools
Exam tags
NEET-PGINICETUSMLEPLABMRCP
Brief (to candidate)
A 34-year-old has daily weals and itch for 5 months without angioedema airway threat. Another patient has chronic itch with normal skin and renal disease. You have 8 minutes to choose antihistamine strategy for urticaria and explain limits in non-histaminergic itch.[1][7]
Candidate instructions
- Distinguish urticaria (weals ± angioedema) from pruritus without primary rash.
- First-line newer-generation H1 antihistamines for CSU; step-up to four-fold the approved dose when standard dosing fails.
- Role of omalizumab if antihistamine-refractory CSU.
- Limits of antihistamines in atopic dermatitis and other non-histaminergic itch.
- Caution with first-generation sedating antihistamines (last resort).
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Urticaria mechanism | Mast-cell histamine drives weals in chronic spontaneous urticaria (CSU) — H1 antihistamines are foundational[1][2] |
| First-line drugs | Prefer newer-generation H1 blockers; CSACI: first-line for allergic rhinitis and urticaria. Usual therapeutic doses in Leelakanok include bilastine 20 mg, desloratadine 5 mg, fexofenadine 120 to 180 mg[1][5] |
| Updosing | If standard dose fails, guidelines recommend step-up second-generation H1-antihistamines to four-fold the approved dose before omalizumab[3] |
| Refractory CSU | Add-on omalizumab (2022 international guideline second-line). Saini: a single subcutaneous 300 mg or 600 mg dose improved UAS7; 75 mg did not. Ciclosporin is off-label (approximately 54 to 73 percent improve)[1][8] |
| When antihistamines fail itch | Atopic dermatitis: oral antihistamines are not recommended because they do not reduce pruritus. Chronic pruritus (Butler): inflammatory ~60 percent first-line topical steroids; neuropathic ~25 percent; uraemic/cholestatic among other systemic causes[4][7] |
| Sedating agents | CSACI: first-generation (diphenhydramine, hydroxyzine) last resort; Pelen: antihistamines a common anticholinergic class in older adults. Do not claim the 2019 Beers abstract names first-generation antihistamines[5][6] |
| Safety-net | Anaphylaxis features: prompt intramuscular adrenaline is first-line, not an antihistamine[9] |
Model key actions
- Start daily newer-generation H1 for CSU; updose to four-fold the approved dose if needed.[1][3]
- Escalate antihistamine-refractory CSU toward omalizumab rather than chronic prednisolone.[1][8]
- Do not expect antihistamines alone to fix atopic dermatitis or systemic non-histaminergic pruritus.[4][7]
Common errors
- Long-term first-generation antihistamines in the elderly as routine.
- Chronic oral corticosteroids for CSU.
- Stopping at standard dose and calling CSU refractory.
- Assuming all itch is histamine-driven.
- Missing airway emergency features (adrenaline first).
References9ShowHide
- [1]Kolkhir P, Bonnekoh H, Metz M, et al. Chronic Spontaneous Urticaria: A Review JAMA, 2024.PMID 39325444
- [2]Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria Nat Rev Dis Primers, 2022.PMID 36109590
- [3]Zuberbier T, Ensina LF, Giménez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment Lancet, 2024.PMID 39004090
- [4]Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment Am Fam Physician, 2020.PMID 32412211
- [5]Fein MN, Fischer DA, O'Keefe AW, et al. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria Allergy Asthma Clin Immunol, 2019.PMID 31582993
- [6]Pelen K, Hagenimana WB, Baroud ML, et al. Prevalence and factors associated with anticholinergic medication use in community-dwelling older adults: a systematic review Int J Clin Pharm, 2025.PMID 41066035
- [7]Butler DC, Berger T, Elmariah S, et al. Chronic Pruritus: A Review JAMA, 2024.PMID 38809527
- [8]Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria J Allergy Clin Immunol, 2011.PMID 21762974
- [9]Muraro A, Worm M, Alviani C, et al. EAACI guidelines: Anaphylaxis (2021 update) Allergy, 2022.PMID 34343358